Screener
Cytokinetics CYTK Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Accrued and other liabilities | (966) | (382) |
| Operating lease liabilities | (3,742) | (4,466) |
| Other non-current liabilities | (7,065) | (41) |
| Net cash used in operating activities | (305,297) | (259,853) |
| Cash flows from investing activities: | ||
| Purchases of investments | (833,781) | (382,071) |
| Investment in non-marketable equity security | — | (5,000) |
| Maturities of investments | 482,539 | 549,725 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's operating cash flow?
- Cytokinetics (CYTK) reported operating cash flow of -$159.84M in Q2 2026.
- How has Cytokinetics's operating cash flow changed year-over-year?
- Cytokinetics's operating cash flow decreased by 24.6% year-over-year, from -$128.24M to -$159.84M.
- What is the long-term trend for Cytokinetics's operating cash flow?
- Over 4 years (2021 to 2025), Cytokinetics's operating cash flow has grown at a 37.5% compound annual growth rate (CAGR), from -$142.52M to -$510.01M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Cytokinetics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude